THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT
https://doi.org/10.17749/2070-4909.2017.10.4.044-052
Abstract
The paper examines the international experience of drug supply and the risks faced by countries using various systems of drug provision to the population in the outpatient settings. The option of introducing a system of drug supply or drug insurance with co-payment by outpatients is discussed.
About the Authors
D. V. Lukyantseva
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution
Russian Federation
Russian Federation
Lukyantseva Daria Valeryevna – PhD, Senior Researcher at the Center for Technology Assessment in Healthcare, the Institute of Applied Economic Research of RANEPA, Head of the Healthcare Finance Center.
Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965
L. S. Mel’nikova
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution
Russian Federation
Russian Federation
Mel’nikova Lyubov’ Sergeevna – MD, Leading research fellow.
Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965
A. P. Tatarinov
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution
Russian Federation
Russian Federation
Tatarinov Anton Petrovich – Researcher at the Center for Technology Assessment in Healthcare, the Institute of Applied Economic Research of RANEPA, Head of the Health Care Finance Center.
Nastasiinsky lane d. 3 p. 2, Moscow, 127006, tel.: +7(495)6998965
References
1. Pharmaceutical Financing Strategies. (MDS-3: Managing Access to Medicines and Health Technologies, Chapter 11), (2012; 18 pages). URL: http://apps.who.int/medicinedocs/documents/s19587en/s19587en.pdf. Accessed: 25.10.2017.
2. World health report: Financing of health systems: A path to universal coverage of health care; World Health Organization 2010 (in Russian). URL: http://www.who.int/whr/2010/whr10_ru.pdf?ua=1. Accessed: 25.10.2017.
3. Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 41. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
4. Geneesmiddelenbulletin. The role of drug bulletins. Retrieved from http://geneesmiddelenbulletin.com/english/the-role-of-drugbulletins/. Accessed: 25.10.2017.
5. Specialisten schrijven specialistisch voor [Specialists prescribe specialist pharmaceuticals]. Pharmaceutisch Weekblad. 2003; 138 (17): 1. URL: http://www.sfk.nl/nieuws-publicaties/PW/2014/opnieuwminder-apotheken. Accessed: 25.10.2017.
6. Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 275. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
7. Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 149-150. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
8. Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Accessed: 25.10.2017.
9. Prins M. A., Hek K., Verberne L., Nielen M., Opperhuizen G., Verheij R. Zorg door de huisarts: jaarcijfers 2014 en trendcijfers 2010-2014 [Care provided by the GP, annual figures 2014 and trend figures 2010-2014]. URL: https://www.nivel.nl/sites/default/files/bestanden/dietist_jaarcijfers_2014.pdf. Accessed: 25.10.2017.
10. Statistics Netherlands (2015). StatLine [online database]. The Hague/Heerlen: Statistics Netherlands. http://statline.cbs.nl. Accessed: 25.10.2017.
11. Batenburg R., Kroneman M., Sagan A. The impact of the crisis on the health system and health in the Netherlands. Economic crisis, health systems and health in Europe. World Health Organization, Regional Office for Europe, European Observatory on Health Systems and Policies. 2015; URL: http://www.euro.who.int/__data/assets/pdf_file/0010/279820/Web-economic-crisis-health-systems-and-healthweb.pdf?ua=1. Accessed: 25.10.2017.
12. Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 151. URL: http://www.euro.who.int/__data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
13. NPCF (2014). Voorlichting aan patiënt bij medicijnuitgifte nog niet in orde [Quality of information to patients at medicine delivery not yet satisfactory]. URL: https://www.patientenfederatie.nl/nieuws/voorlichting-aan-patient-bij-medicijnuitgifte-nog-niet-in-orde. Accessed: 25.10.2017.
14. Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/data-en-feiten-2015/view. Accessed: 25.10.2017.
15. GlobalData, Singapore’s pharmaceutical market value to reach $1.15 billion by 202. URL: https://www.globaldata.com/singaporespharmaceutical-market-value-reach-1-15-billion-2021. Accessed: 25.10.2017.
16. Pharmaceutical Inspection Co-operation Scheme. URL: https://www.picscheme.org/en/members?paysselect=SG. Accessed: 25.10.2017.
17. GKV-Spitzenverband (2009). GKV-Arzneimittel-Schnellinformation (GAmSi). Essen, GKV-Spitzenverband. URL: http://www.gkv-gamsi.de. Accessed: 25.10.2017.
18. Verband der forschenden Pharma-Unternehmen (2012). General political situation. URL: https://www.vfa.de. Accessed: 25.10.2017.
19. Statistisches Bundesamt (2014). Statistisches jahrbuch Deutschland und Internationales. URL: https://www.destatis.de/DE/Publikationen/StatistischesJahrbuch/StatistischesJahrbuch2014.pdf?__blob=publicationFile. Accessed: 25.10.2017.
20. Schaufler J., Telschow C. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U., Paffrath D., eds. Arzneiverordnungs-Report. 2013; 967-981. URL: https://link.springer.com/chapter/10.1007/978-3-642-37124-0_47. Accessed: 25.10.2017.
21. Schaufler J., Telschow C. Überblick über die Arzneiverordnungen nach Arztgruppen. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport 2013; 955-966. URL: https://link.springer.com/content/pdf/bfm%3A978-3-642-37124-0%2F1.pdf. Accessed: 25.10.2017.
22. Bundesverband der Arzneimittel-Hersteller. Der Arzneimittelmarkt in Deutschland in Zahlen. Verordnungsmarkt und Selbstmedikation 2009. Bonn, Bundesverband der Arzneimittel-Hersteller. URL: https://www.bah-bonn.de/bah/?type=565&file=redakteur_filesystem%2Fpublic%2Fmarkt_zahlen_broschuere_2010.pdf. Accessed: 25.10.2017.
23. OECD (2013). Health data 2011, 2012, 2013. Paris, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Data obrashcheniya: 25.10.2017.
24. Menon D., Stafinski T. Health technology assessment in Canada: 20 years strong? Value in Health. 2009; 12 (2): 14-19.
25. Flood C. M. The evidentiary burden for overturning government’s choice of regulatory instrument: the case of direct-to-consumer advertising of prescription drugs. University of Toronto Law Journal. 2010; 60 (2): 397-424.
26. Mintzes B. s soavt. Influence of direct to consumer advertising and patients’ requests on prescribing decisions: two site cross sectional survey. BMJ. 2002; 324: 278-279.
27. Paris V., Docteur E. Pharmaceutical pricing and reimbursement policies in Canada. Paris, (Health Working Paper). Organisation for Economic Co-operation and Development. URL: http://www.oecdilibrary.org/social-issues-migration-health/pharmaceutical-pricingand-reimbursement-policies-in-canada_346071162287?crawler=true. Accessed: 25.10.2017.
28. Health systems: the time of change. Review summary: Canada, 2012; European Observatory on Health Systems and Policies (in Russian). URL: http://www.euro.who.int/__data/assets/pdf_file/0010/184672/Summary-HiT-Canada-2013-Rus.pdf?ua=1. Accessed: 26.01.2018.
29. Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://publications.gc.ca/collections/Collection/CP32-85-2002E.pdf. Accessed: 25.10.2017.
30. McMahon M., Morgan S., Mitton C. The Common Drug Review: a NICE start for Canada? Health Policy. 2006; 77 (3): 339-351.
31. Menon D., Stafinski T., Stuart G. Access to drugs for cancer: does where you live matter? Canadian Journal of Public Health. 2005; 96 (6): 454-458.
32. Grootendorst P., Hollis A. Managing pharmaceutical expenditures: overview and options for Canada. Ottawa, Canadian Health Services Research Foundation. URL: http://www.cfhi-fcass.ca/Libraries/Hospital_Funding_docs/CHSRF-GrootendorstPharmaExpenditures.sflb.ashx. Accessed: 25.10.2017
33. McLeod L. et al. Financial burden of household out-of-picket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Medicine. 2011; 5 (1): 1-9.
34. Pomey M. P. et al. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec’s universal drug insurance program, with comparisons to the medicare Prescription Drug program. Milbank Quarterly. 2007; 85 (3): 469-498.
35. Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://www.cbc.ca/healthcare/final_report.pdf. Accessed: 25.10.2017.
36. Campbell B., Marchildon G. P. s soavt. Federal Pharmacare: prescription for an ailing federation? Medicare: facts, myths, problems and promise. Toronto, Lorimer. 2007; 268-284.
37. OECD (2014). Health at a glance: Europe 2014. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Accessed: 25.10.2017.
38. OECD (2012). Pharmaceutical spending. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Accessed: 25.10.2017.
39. O’Neill C., McGregor P., Merkur S. United Kingdom (Northern Ireland) health system review. Health Systems in Transition. 2012; 14 (10): 1-90.
40. Health & Social Care Information Centre (2014). Prescription dispensed in the community, Statistics for England, 2003-2013. URL: https://digital.nhs.uk/catalogue/PUB14414. Accessed: 25.10.2017.
41. Department of Health (2013). Government agrees breakthrough drug pricing deal with pharmaceutical firms. London, Department of Health. URL: https://www.gov.uk/government/news/governmentagrees-breakthrough-drug-pricing-deal-with-pharmaceutical-firms. Accessed: 25.10.2017.
42. Lu Y. s soavt. Medicine expenditures. In: The world medicines situation. Geneva, World Health Organization. 2010. URL: http://dosei.who.int/. Accessed: 25.10.2017.
Review
For citations:
Lukyantseva D.V., Mel’nikova L.S., Tatarinov A.P. THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(4):44-52. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.4.044-052
Views:
1715
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 